Home

Bafna Pharmaceuticals Ltd EPS

Image

Bafna Pharmaceuticals Ltd

NSE: BAFNAPH

EPS

₹ 1.97

Last updated on: May 09, 2025

Key Highlights

  • The Earning per Share of Bafna Pharmaceuticals Ltd is ₹ 1.97 as of 09 May 25 .
  • The earning per share of Bafna Pharmaceuticals Ltd changed from ₹ 2.68 to ₹ 0.4 over 7 quarters. This represents a CAGR of -66.27% .

Historical Earning per Share of Bafna Pharmaceuticals Ltd

No data available

* All values are in

Company Fundamentals for Bafna Pharmaceuticals Ltd

Market Cap

170 Cr

EPS

2.0

P/E Ratio (TTM)

36.5

P/B Ratio (TTM)

2.1

Day’s High

75.0

Day’s Low

72.75

DTE

0.2

ROE

0.9

52 Week High

99.75

52 Week Low

67.8

ROCE

3.2

Market Price of Bafna Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Bafna Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
08 May 202572.76
07 May 202571.65
06 May 202575
05 May 202576.57
02 May 202580.6
30 Apr 202577.23
29 Apr 202579
28 Apr 202582.41
25 Apr 202579.74
24 Apr 202575.95

SWOT Analysis Of Bafna Pharmaceuticals Ltd

Strength

2

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Bafna Pharmaceuticals Ltd

Asset Value vs Market Value of Bafna Pharmaceuticals Ltd

Market Value

170

Asset Value

Value addition

3.7 X

36

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Bafna Pharmaceuticals Ltd170.33
Sun Pharmaceutical Industries Ltd418648
Divis Laboratories Ltd159310
Cipla Ltd119410
Torrent Pharmaceuticals Ltd106184
Mankind Pharma Ltd99570

Historical Market Cap of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Bafna Pharmaceuticals Ltd News Hub

Bafna Pharmaceuticals reports standalone net loss of Rs 0.72 crore in the June 2024 quarter

Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024 as agains

Read more

13 Aug 24

Bafna Pharmaceuticals to declare Quarterly Result

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024

Read more

10 Aug 24

Bafna Pharmaceuticals to convene AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on

Read more

04 Sept 24

Bafna Pharmaceuticals schedules AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on

Read more

05 Sept 24

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Bafna Pharmaceuticals Ltd

What is the EPS of Bafna Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Bafna Pharmaceuticals Ltd is 1.97. An EPS is the amount of net income attributed to each share of a common stock.

How is Bafna Pharmaceuticals Ltd EPS calculated?

The EPS of Bafna Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Bafna Pharmaceuticals Ltd report its EPS?

Bafna Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Bafna Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Bafna Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Bafna Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Bafna Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions